Geron to Present at 2019 Cantor Global Healthcare Conference

MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference in New York at 9:30 a.m.

Metadata
Provider: 
GlobeNewswire, Inc.
Retrieved on: 
Thursday, September 26, 2019
Information
Tags: 
Branches of biology, Biotechnology, Life sciences, Stem cells, Geron Corporation, Geron, Telomerase
Geotags: 
Menlo Park, Us
Organisation: 
GERON CORPORATION
Summary
Key Points: 
  • MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference in New York at 9:30 a.m.
  • ET on Friday, October 4, 2019.
  • If you are unable to listen to the live presentation, an archived webcast will be available on the Companys website for 30 days.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.



MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference in New York at 9:30 a.m. ET on Friday, October 4, 2019.

A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Suzanne Messere
Investor and Media Relations
[email protected]
[email protected]

CG Capital
877-889-1972

Primary Logo
Copyright: 
2019 GlobeNewswire, Inc.. All Rights Reserved.